A retrospective study comparing the effects of sodium‐glucose Co‐transporter‐2 inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors on renal function preservation in patients with type 2 diabetes in Japan
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Ipragliflozin (Primary) ; Luseogliflozin (Primary) ; Tofogliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 30 Sep 2020 New trial record